211 related articles for article (PubMed ID: 33386662)
1. Biological stratification of clinical disease courses in childhood immune thrombocytopenia.
Schmidt DE; Heitink-Pollé KMJ; Mertens B; Porcelijn L; Kapur R; van der Schoot CE; Vidarsson G; van der Bom JG; Bruin MCA; de Haas M
J Thromb Haemost; 2021 Apr; 19(4):1071-1081. PubMed ID: 33386662
[TBL] [Abstract][Full Text] [Related]
2. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia.
Schmidt DE; Wendtland Edslev P; Heitink-Pollé KMJ; Mertens B; Bruin MCA; Kapur R; Vidarsson G; van der Schoot CE; Porcelijn L; van der Bom JG; Rosthøj S; de Haas M
J Thromb Haemost; 2021 Jan; 19(1):121-130. PubMed ID: 33058474
[TBL] [Abstract][Full Text] [Related]
3. Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.
Schmidt DE; Heitink-Pollé KMJ; Laarhoven AG; Bruin MCA; Veldhuisen B; Nagelkerke SQ; Kuijpers TW; Porcelijn L; van der Schoot CE; Vidarsson G; de Haas M
Blood Adv; 2019 Jul; 3(13):2003-2012. PubMed ID: 31270082
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.
Heitink-Pollé KMJ; Uiterwaal CSPM; Porcelijn L; Tamminga RYJ; Smiers FJ; van Woerden NL; Wesseling J; Vidarsson G; Laarhoven AG; de Haas M; Bruin MCA;
Blood; 2018 Aug; 132(9):883-891. PubMed ID: 29945954
[TBL] [Abstract][Full Text] [Related]
5. Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.
Schmidt DE; Heitink-Polle KMJ; Porcelijn L; van der Schoot CE; Vidarsson G; Bruin MCA; de Haas M
J Thromb Haemost; 2020 May; 18(5):1210-1220. PubMed ID: 32053276
[TBL] [Abstract][Full Text] [Related]
6. Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.
Morimoto Y; Yoshida N; Kawashima N; Matsumoto K; Kato K
Int J Hematol; 2014; 99(5):597-602. PubMed ID: 24573984
[TBL] [Abstract][Full Text] [Related]
7. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study.
Peng J; Ma SH; Liu J; Hou Y; Liu XM; Niu T; Xu RR; Guo CS; Wang XM; Cheng YF; Ni H; Hou M
J Thromb Haemost; 2014 Apr; 12(4):497-504. PubMed ID: 24517219
[TBL] [Abstract][Full Text] [Related]
8. IVIg treatment increases thrombin activation of platelets and thrombin generation in paediatric patients with immune thrombocytopenia.
Schmugge M; Franzoso FD; Winkler J; Kroiss S; Seiler M; Speer O; Rand ML
Br J Haematol; 2023 Jun; 201(6):1209-1219. PubMed ID: 36861460
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatricm immune thrombocytopenia.
Chen YY; Zhou YQ; Zhao N; Zhang Y; Xu WQ; Tang YM
Cytokine; 2019 Aug; 120():234-241. PubMed ID: 31129375
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T
J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
Hong J; Bang SM; Mun YC; Yhim HY; Lee J; Lim HS; Oh D;
J Korean Med Sci; 2018 May; 33(19):e142. PubMed ID: 29736158
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia.
Papagianni A; Economou M; Tragiannidis A; Karatza E; Tsatra I; Gombakis N; Athanassiadou-Piperopoulou F; Athanasiou-Metaxa M
J Pediatr Hematol Oncol; 2011 May; 33(4):265-9. PubMed ID: 21516022
[TBL] [Abstract][Full Text] [Related]
13. Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.
Yildiz I; Ozdemir N; Celkan T; Soylu S; Karaman S; Canbolat A; Dogru O; Erginoz E; Apak H
Pediatr Hematol Oncol; 2015; 32(6):406-14. PubMed ID: 26154620
[TBL] [Abstract][Full Text] [Related]
14. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
[TBL] [Abstract][Full Text] [Related]
15. A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group.
Neunert C; Heitink-Polle KMJ; Lambert MP
Br J Haematol; 2023 Oct; 203(1):17-22. PubMed ID: 37641973
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura.
Higashide Y; Hori T; Yoto Y; Kabutoya H; Honjo S; Sakai Y; Nojima M; Yoda M; Yamamoto M; Tsutsumi H
Pediatr Int; 2018 Apr; 60(4):357-361. PubMed ID: 29297955
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
Watts RG
Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulins ameliorate thrombin-related platelet functions in childhood immune thrombocytopenia.
Kapur R
Br J Haematol; 2023 Jun; 201(6):1019-1020. PubMed ID: 36924289
[TBL] [Abstract][Full Text] [Related]
20. [Influencing Factors in the Chronicity of Immune Thrombocytopenia in Children].
Wang LY; Liu KK; Chu JH; Yang LH; Xie ZW; Zhang KL; Chai HJ; Wu ZY; Wang NL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):881-886. PubMed ID: 34105488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
